Inventor · disambiguated record
Sabine K. Ruppel
Also filed as: RUPPEL SABINE · RUPPEL SABINE K
14 granted patents·9 pending applications·52 citations·filing 2017–2024
89Inventor score
Files withFOGHORN THERAPEUTICS INC15BOEHRINGER INGELHEIM INT5IKENA ONCOLOGY INC2FORMA THERAPEUTICS INC1
Top patents by PatentIndex Score
23 records- 0195US11560381B1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2022·Granted Jan 24, 2023·12 cites·12 claims
- 0295US11414416B1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Granted Aug 16, 2022·16 cites·15 claims
- 0394US11851445B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Granted Dec 26, 2023·9 cites·6 claims
- 0492US11787800B2BRD9 degraders and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Granted Oct 17, 2023·3 cites·24 claims
- 0592US11773085B2Methods and compounds for treating disordersFOGHORN THERAPEUTICS INC·Filed 2020·Granted Oct 3, 2023·10 cites·4 claims
- 0684US2025042901A1Heteroaryl carboxamide compounds as inhibitors of ripk2BOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 0778US11130754B2Substituted benzamides as RIPK2 inhibitorsBOEHRINGER INGELHEIM INT·Filed 2018·Granted Sep 28, 2021·1 cites·14 claims
- 0875US12139484B2Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel diseaseBOEHRINGER INGELHEIM INT·Filed 2021·Granted Nov 12, 2024·0 cites·23 claims
- 0974US12351579B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Granted Jul 8, 2025·0 cites·18 claims
- 1074US10138241B2Substituted benzamides as RIPK2 inhibitorsBOEHRINGER INGELHEIM INT·Filed 2017·Granted Nov 27, 2018·1 cites·52 claims
- 1172US12459895B2MEK inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2023·Granted Nov 4, 2025·0 cites·20 claims
- 1272US2024166668A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1371US2024150348A1Brd9 degraders and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1469US2024150328A1Methods and compounds for treating disordersFOGHORN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1568US11878958B2MEK inhibitors and uses thereofIKENA ONCOLOGY INC·Filed 2023·Granted Jan 23, 2024·0 cites·22 claims
- 1667US2023142883A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1765US2023066136A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1853US2023348452A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1948US12391686B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2020·Granted Aug 19, 2025·0 cites·22 claims
- 2048US12384776B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2020·Granted Aug 12, 2025·0 cites·17 claims
- 2148US2023065463A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2248US2022041597A1Inhibiting ubiquitin specific peptidase 9xFORMA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2339US10138222B2Substituted benzamides as RIPK2 inhibitorsBOEHRINGER INGELHEIM INT·Filed 2017·Granted Nov 27, 2018·0 cites·33 claims
Join the waitlist — get patent alerts
Get an alert when Sabine K. Ruppel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →